Minnesota 2025 Regular Session Status: In Committee Sponsors 1 D

HF 5147 — Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required.

Last action — Introduction and first reading, referred to Taxes

Write to your legislator about it: a free email template →

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced May 14, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

In plain language

Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required.

Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required.

Summary

Relating to taxation; individual income and corporate franchise tax; requiring an addition for certain pharmaceutical marketing expenses.

In the bill's own words, from its opening clause.

Bill Text

How this bill changes current law

2 changes Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

The bill adds new provisions regarding the taxation of pharmaceutical marketing expenses in Minnesota.

  • Minnesota Statutes 2024, section 290.0131

    Subd. 21. Pharmaceutical marketing expenses. (a) For the purposes of this subdivision, the following terms have the meanings given: (1) "direct-to-consumer pharmaceutical marketing" means advertising, marketing, or promotional activities directed toward consumers in the United States that are intended to promote the use, purchase, or prescription of a prescription drug or biologic, including television, radio, print, digital, and social media advertising, as well as patient-directed outreach and disease awareness campaigns funded by a pharmaceutical manufacturer and linked to a specific product; and (2) "pharmaceutical manufacturer" means a person or entity engaged in the production, preparation, propagation, compounding, or processing of prescription drugs or biologics. (b) The amount deducted under section 162 of the Internal Revenue Code for direct-to-consumer pharmaceutical marketing is an addition.

    This new subdivision establishes defined terms related to pharmaceutical marketing expenses and specifies that amounts deducted under federal tax law for these expenses must be added back for state tax purposes.

  • Minnesota Statutes 2024, section 290.0133

    Subd. 16. Pharmaceutical marketing expenses. The amount deducted under section 162 of the Internal Revenue Code for direct-to-consumer pharmaceutical marketing is an addition. For purposes of this subdivision, "direct-to-consumer pharmaceutical marketing" has the meaning provided in section 290.0131, subdivision 21.

    This new subdivision specifies that certain amounts related to pharmaceutical marketing expenses must be added for state tax calculations, linked to the definition established in section 290.0131.

Action History

  1. Introduction and first reading, referred to Taxes

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 202 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (202)

202 members have not signed on to this bill.

Show all 202 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Committees

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HF 5147 do?
Relating to taxation; individual income and corporate franchise tax; requiring an addition for certain pharmaceutical marketing expenses.
Who sponsors HF 5147?
HF 5147 is sponsored by Robert Bierman (Democratic-Farmer-Labor).
What is the current status of HF 5147?
This bill is in committee in the House. Introduced May 14, 2026. It must pass committee before a floor vote.
Where can I track HF 5147?
Track HF 5147 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HF 5147

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HF 5147

Last checked for changes 18 days ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →